FDA 483 - Reliance Life Sciences Private Limited - February 27, 2026
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Reliance Life Sciences Private Limited in Navi Mumbai revealed critical deficiencies across its quality control and manufacturing operations. The firm was cited for significant data integrity issues, including falsified environmental monitoring records and manipulated microbial limit test results for active pharmaceutical ingredients. Additionally, the inspection found inadequate aseptic processing controls, including poor sterilization validation, deficient media fills, and compromised cleanroom practices, alongside a severely lacking deviation management system that failed to investigate equipment malfunctions impacting product quality.
ID · 43ee35e0-0c20-4849-9f73-a6f046f78841